This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Jun;16(6):383.

doi: 10.1038/nrd.2017.103. Epub 2017 May 19.

Cancer immunotherapy: T cells get a ride

M Teresa Villanueva

PMID: 28529320
DOI: 10.1038/nrd.2017.103

Comment

Cancer immunotherapy: T cells get a ride

M Teresa Villanueva. Nat Rev Drug Discov. 2017 Jun.

. 2017 Jun;16(6):383.

doi: 10.1038/nrd.2017.103. Epub 2017 May 19.

Author

M Teresa Villanueva

PMID: 28529320
DOI: 10.1038/nrd.2017.103

No abstract available

PubMed Disclaimer

Comment on

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.
Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH, Laoui D, De Palma M. Schmittnaegel M, et al. Sci Transl Med. 2017 Apr 12;9(385):eaak9670. doi: 10.1126/scitranslmed.aak9670. Sci Transl Med. 2017. PMID: 28404865
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G. Allen E, et al. Sci Transl Med. 2017 Apr 12;9(385):eaak9679. doi: 10.1126/scitranslmed.aak9679. Sci Transl Med. 2017. PMID: 28404866 Free PMC article.

Similar articles

Immunotherapy: T cells get a ride.
Villanueva MT. Villanueva MT. Nat Rev Cancer. 2017 May 24;17(6):333. doi: 10.1038/nrc.2017.39. Nat Rev Cancer. 2017. PMID: 28536454 No abstract available.
Immunotherapy: CD8⁺ T cells - burn fat, get fit.
Bradley CA. Bradley CA. Nat Rev Cancer. 2017 Nov;17(11):635. doi: 10.1038/nrc.2017.94. Epub 2017 Oct 6. Nat Rev Cancer. 2017. PMID: 28984292 No abstract available.
A dual role for genetically modified lymphocytes in cancer immunotherapy.
Russo V, Bondanza A, Ciceri F, Bregni M, Bordignon C, Traversari C, Bonini C. Russo V, et al. Trends Mol Med. 2012 Apr;18(4):193-200. doi: 10.1016/j.molmed.2011.12.003. Epub 2012 Jan 7. Trends Mol Med. 2012. PMID: 22230382 Review.
Cancer-killing CAR therapies gain speed.
Weber M. Weber M. Cancer Discov. 2015 Jan;5(1):7. doi: 10.1158/2159-8290.CD-ND2014-013. Epub 2015 Jan 5. Cancer Discov. 2015. PMID: 25583785
A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy.
Vonderheide RH, June CH. Vonderheide RH, et al. Immunol Res. 2003;27(2-3):341-56. doi: 10.1385/IR:27:2-3:341. Immunol Res. 2003. PMID: 12857980 Review.

See all similar articles

References

1. Sci Transl Med. 2017 Apr 12;9(385):null - PubMed
1. Sci Transl Med. 2017 Apr 12;9(385):null - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations